NCT01749410已完成不适用
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 33
- 主要终点
- Change From Baseline in the Number of Headache Days
研究概览
简要总结
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •15 or more headache days over a 30 day period
- •A minimum of 7 treatment cycles with onabotulinumtoxinA
排除标准
- •Any treatment cycle dose of onabotulinumtoxinA greater than 200 units
结局指标
主要结局
Change From Baseline in the Number of Headache Days
时间窗: Treatment Cycle 7 (approximately 1.5 years)
The mean number of headache days was counted as the number of headache days occurring during the 30 day period ending with treatment cycle 7. Each treatment cycle was administered approximately every 12 weeks.
次要结局
未报告次要终点
研究者
相似试验
撤回
不适用
A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic MigrainesChronic Migraine, HeadacheNCT01749423Allergan
招募中
不适用
OnaBotulinumtoxin-A in Chronic Migraine Patients With Short or Long Disease History (the BACH Study)MigraineNCT06537700Fondazione Policlinico Universitario Campus Bio-Medico115
已完成
3 期
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)Urinary IncontinenceMultiple SclerosisNeurogenic BladderNCT01600716Allergan144
已完成
不适用
Toxin Retrospective StudyNeurogenic BladderNCT03042052Centre d'Investigation Clinique et Technologique 805292
已完成
不适用
An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type AFacial RhytidesNCT01608659Allergan110